In the final draft guidance, NICE recommended Kiskali be taken out of the Cancer Drugs Fund, which has been providing interim reimbursement since 2019 until further trial data emerged addressing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback